Agenus Inc (AGEN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Agenus Inc stock (AGEN) is currently trading at $3.56. Agenus Inc PS ratio (Price-to-Sales) is 1.25. Analyst consensus price target for AGEN is $12.33. WallStSmart rates AGEN as Underperform.
- AGEN PE ratio analysis and historical PE chart
- AGEN PS ratio (Price-to-Sales) history and trend
- AGEN intrinsic value — DCF, Graham Number, EPV models
- AGEN stock price prediction 2025 2026 2027 2028 2029 2030
- AGEN fair value vs current price
- AGEN insider transactions and insider buying
- Is AGEN undervalued or overvalued?
- Agenus Inc financial analysis — revenue, earnings, cash flow
- AGEN Piotroski F-Score and Altman Z-Score
- AGEN analyst price target and Smart Rating
Agenus Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Agenus Inc (AGEN) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, operating margin, price/sales. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Agenus Inc (AGEN) Key Strengths (4)
Keeps $42 of every $100 in revenue after operating costs
Good growth relative to its price
Paying $1.25 for every $1 of annual revenue
Strong revenue growth at 27.50% annually
Supporting Valuation Data
Agenus Inc (AGEN) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 218.6x book value
Very thin margins, barely profitable
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Agenus Inc (AGEN) Detailed Analysis Report
Overall Assessment
This company scores 46/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 4 register as strengths (avg 8.5/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, PEG Ratio, Price/Sales. Valuation metrics including PEG Ratio (1.44), Price/Sales (1.25) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 42.10%. Growth metrics are encouraging with Revenue Growth at 27.50%.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Profit Margin. Some valuation metrics including Price/Book (218.61) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -1279.00%, Profit Margin at 0.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1279.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 27.50% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AGEN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AGEN's Price-to-Sales ratio of 1.25x trades at a deep discount to its historical average of 34.92x (2th percentile). The current valuation is 100% below its historical high of 361.43x set in Feb 2006, and 26% above its historical low of 0.99x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~1.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Agenus Inc (AGEN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Agenus Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 114M with 28% growth year-over-year. Profit margins are thin at 10.0%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 28% YoY, reaching 114M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -0.17 indicates a conservative balance sheet with 3M in cash.
Free cash flow is -17M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can Agenus Inc push profit margins above 15% as the business scales?
Growth sustainability: can Agenus Inc maintain 28%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.67, so expect amplified moves relative to the broader market.
Debt management: total debt of 46M is significantly higher than cash (3M). Monitor refinancing risk.
Bottom Line
Agenus Inc offers an attractive blend of growth (28% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Agenus Inc(AGEN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.